Denali Therapeutics (NASDAQ:DNLI) Shares Up 9.3% – Still a Buy?

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) were up 9.3% during trading on Wednesday . The stock traded as high as $23.66 and last traded at $23.97. Approximately 474,482 shares traded hands during mid-day trading, a decline of 73% from the average daily volume of 1,745,651 shares. The stock had previously closed at $21.93.

Analysts Set New Price Targets

A number of equities analysts have commented on DNLI shares. Wedbush reduced their price objective on Denali Therapeutics from $25.00 to $23.00 and set an “outperform” rating on the stock in a research note on Friday, May 8th. Leerink Partners reduced their price objective on Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 22nd. Stifel Nicolaus boosted their price objective on Denali Therapeutics from $34.00 to $41.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Wolfe Research started coverage on Denali Therapeutics in a research note on Monday, February 23rd. They issued a “peer perform” rating on the stock. Finally, HC Wainwright boosted their price objective on Denali Therapeutics from $32.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $34.25.

Denali Therapeutics Stock Up 8.8%

The business has a fifty day moving average of $19.86 and a 200 day moving average of $19.49. The firm has a market cap of $3.79 billion, a P/E ratio of -8.28 and a beta of 1.03. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04. During the same period in the prior year, the company posted ($0.78) earnings per share. On average, equities research analysts predict that Denali Therapeutics Inc. will post -2.77 EPS for the current year.

Institutional Investors Weigh In On Denali Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Headlands Technologies LLC bought a new stake in Denali Therapeutics in the second quarter valued at about $26,000. Johnson Financial Group Inc. bought a new stake in shares of Denali Therapeutics in the third quarter worth about $29,000. State of Wyoming bought a new stake in shares of Denali Therapeutics in the second quarter worth about $29,000. Fifth Third Bancorp bought a new stake in shares of Denali Therapeutics in the first quarter worth about $55,000. Finally, Aster Capital Management DIFC Ltd bought a new stake in shares of Denali Therapeutics in the fourth quarter worth about $57,000. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.